MedReleaf announced a partnership with the Ontario Clinical Oncology Group for a cancer trial to investigate the management of cancer pain with cannabis oil.
MedReleaf (TSX:LEAF) announced a partnership with the Ontario Clinical Oncology Group (OCOG) for a cancer trial to investigate the management of cancer pain with cannabis oil.
As quoted in the press release:
The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamiltonover a one-two year period. Patients with cancer related pain will be administered MedReleaf’s uniquely formatted cannabis oil capsules with the objective of improving pain management.
Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information